Letter from CGS to members of the California Institute for Regenerative Medicine's Independent Citizens Oversight Committee
By Marcy Darnovsky
| 02. 02. 2005
Dear Members of the Independent Citizens Oversight Committee:
The California public has given you the responsibility to oversee
an enormous undertaking of great potential: the largest state-funded
research program in U.S. history. The Center for Genetics and
Society supports the public funding of embryonic stem cell research
but is concerned that the new California Institute for Regenerative
Medicine (CIRM) is off to a stumbling start with regard to public
transparency and accountability. Although these are not due
to explicit decisions by your committee, you are in a position
to remedy them.
There are three particularly troubling areas of concern.
Conflict of interest regulations. This week the National
Institutes of Health - in many ways a federal analogy to your
own enterprise - announced that it is significantly strengthening
its regulations to curtail conflicts of interest. This highlights
a growing awareness that the conduct and oversight of biomedical
research requires strict protections. Yet the ICOC is failing
to make this a priority. Although it is mandated to adopt standards
"initially based" on those of the NIH for its employees
and...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...